MDxHealth (MDXH) EBITDA (2021 - 2026)

MDxHealth has reported EBITDA for 6 years, with the latest figure at -$4.3 million in Q1 2026.

• Quarterly EBITDA fell 226.0% year-over-year to -$4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 64.15% YoY) and the FY2025 annual result came in at -$1.1 million, up 92.29% from the prior year.
• EBITDA declined to -$4.3 million in Q1 2026 per MDXH's latest filing, from -$2.1 million in the prior quarter.
• Over five years, EBITDA peaked at $7.8 million in Q2 2022 and troughed at -$17.7 million in Q2 2023.
• A 5-year average of -$4.5 million and a median of -$4.4 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA sank 326.33% in 2023, then jumped 127.82% in 2025.
• Over 5 years, EBITDA stood at -$8.9 million in 2022, then surged by 51.15% to -$4.4 million in 2023, then soared by 68.47% to -$1.4 million in 2024, then tumbled by 53.27% to -$2.1 million in 2025, then tumbled by 105.45% to -$4.3 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$4.3 million, -$2.1 million, and $981000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.